Artivion announces presentation of new clinical data for on-x aortic heart valve and amds at the 104th american association for thoracic surgery (aats) annual meeting

5-year real-world safety and efficacy data from on-x aortic heart valve low inr post-market study demonstrate even better patient outcomes than predicted by the proact ide study late-breaking 30-day data from amds persevere trial demonstrate positive aortic remodeling outcomes and zero dane tears atlanta , april 29, 2024 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from the on-x low inr post-market study and amds persevere trial at the 104th american association for thoracic surgery (aats) annual meeting in toronto, canada. presentations highlighted 5-year real-world safety and efficacy data from the on-x aortic heart valve low inr post-market study that demonstrate even better patient outcomes than predicted by the on-x aortic heart valve proact ide study, as well as late-breaking data from the amds persevere trial demonstrating, at 30-days post-amds implantation, positive aortic remodeling outcomes and zero distal anastomotic new entry (dane) tears.
AORT Ratings Summary
AORT Quant Ranking